Palvella Therapeutics PVLA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.3M-18.2% | -$41.72M-19.0% | -$35.07M-31.8% | -$26.61M-28.4% | -$20.73M-37.5% | ||
| $8.68M+35.7% | $6.4M+39.6% | $4.59M+53.1% | $2.99M+68.4% | $1.78M+114% | ||
| -$29.1M-16.4% | -$25.01M+1.8% | -$25.47M-25.3% | -$20.34M-23.2% | -$16.51M-52.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $85.89M-1.4% | ||
| $130.77M+610% | -$25.62M-152% | $49.36M-12.2% | $56.23M-19.3% | $69.71M-9.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Palvella Therapeutics generate?
- Palvella Therapeutics (PVLA) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Palvella Therapeutics's free cash flow?
- Palvella Therapeutics's free cash flow was -$15.2M over the trailing twelve months, up 67.1% year over year.
- Where does Palvella Therapeutics's cash flow data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
